# Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP

> **NCT07497620** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 12 (estimated)

## Conditions studied

- Pityriasis Rubra Pilaris

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT07497620
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07497620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07497620, "Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07497620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*